Trials / Completed
CompletedNCT06520514
A Study to Test How Well Healthy People Tolerate Spesolimab When Given in 2 Different Ways
Safety, Tolerability, and Relative Bioavailability of a Single Dose of Spesolimab Via Two Subcutaneous Modes of Delivery in Healthy Subjects (Mono-centric, Randomised, Parallel Group Design)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The main objectives of this trial is to investigate the safety and tolerability of a single dose of spesolimab administered in 2 different ways in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Spesolimab | Spesolimab |
Timeline
- Start date
- 2024-08-07
- Primary completion
- 2025-01-15
- Completion
- 2025-02-04
- First posted
- 2024-07-25
- Last updated
- 2025-06-29
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT06520514. Inclusion in this directory is not an endorsement.